Genentech says Phase III CELESTIMO trial shows Lunsumio-lenalidomide improves progression-free survival in relapsed follicular lymphoma
Next steps
Results have not been presented yet; data are slated for an upcoming medical meeting, with regulatory submissions planned.
Overall survival and safety findings
Overall survival data were not yet mature at the interim analysis.
Safety matched known profiles for the drugs with no new signals, supporting an outpatient, simplified dosing approach.
Phase III CELESTIMO meets primary endpoint
Genentech reported its Phase III CELESTIMO trial met the primary endpoint in relapsed or refractory follicular lymphoma.
The Lunsumio-lenalidomide regimen extended the time patients lived without disease worsening versus Rituxan-lenalidomide.
